Tick, tock… funding calls for both aging clocks and psychedelics and longevity grant proposals

Longevity Science Foundation is funding research that will establish a longer and healthier human lifespan

The Longevity Science Foundation, which has committed $1 billion over the next ten years to research, institutions and projects advancing healthy human longevity, is calling for funding proposals in two exciting areas: aging clocks and psychedelics and longevity.

Longevity.Technology: The Longevity Science Foundation is a nonprofit organisation that seeks to advance human longevity by funding research and development of medical technologies that can extend the healthy human lifespan. Its long-term mission is to help make longevity-focused care accessible to everyone, no matter their background, by bringing cutting-edge science on aging out of the laboratory and into the mainstream, and it has set itself the goal of extending the healthy lifespan to more than 120 years. And it plans to crack on, investing in projects that can realise rapid change and that will make “a significant difference in people’s lives as soon as possible”.

Aging Clocks

The LSF’s first funding call is centred around the concept of aging clocks, and extends to apps, software and other devices designed specifically to track one’s biological age. And like all clocks, this one on this is ticking, with interested applicants having only until midnight ET on 31st December 2022 to submit their proposals for funding.

The recent discoveries around aging biomarkers and aging clocks have significantly benefited the longevity sector, helping accelerate development of diagnostics, treatments and more. Aging clocks are a valuable tool for researchers, as biomarkers can help determine an individual’s biological age based on the status of cells, tissues and other body systems. As the sector moves toward a more nuanced understanding of the science around aging clocks, stakeholders will be able to unlock a more comprehensive and holistic assessment of someone’s health. Aging clocks also facilitate means for researchers to measure the efficacy of antiaging treatments.

Six-compound drug discovery collaboration will leverage cutting-edge AI tech.
Dr Alex Zhavoronkov

Alex Zhavoronkov, who is a member of the LSF Visionary Board says: “Predictors of chronological and biological age developed using deep learning (DL) are rapidly gaining popularity in the aging research community. These deep aging clocks can be used in a broad range of applications in the pharmaceutical industry, spanning target identification, drug discovery, data economics and synthetic patient data generation [1].”

The deadline for proposals is December 31st at 00:00 ET. To apply, visit https://longevity.foundation/apply.

Psychedelics and Longevity

While not typically discussed as such, mental and brain health are crucial components of human longevity. Psychedelic applications for mental health treatments are rapidly accelerating, with compounds like ketamine, MDMA and psilocybin showing promising results in treating PTSD, depression, and addiction. Researchers have also proven ketamine and psilocybin can help regrow neural connections, a potentially groundbreaking finding in developing future treatments for aging-related neurodegenerative diseases.

It’s a space that is rapidly accelerating; entrepreneur and investor Christian Angermayer counts himself as “one of the driving forces behind the psychedelics renaissance”, saying that compounds such as psilocybin are have the potential to treat a wide range of mental health conditions. Indeed, his company atai Life Sciences has a pipeline of more than ten therapeutic candidates targeted at some of the world’s most prevalent and damaging mental health illnesses, including depression, anxiety and addiction.

This new funding call, which is joint effort between the LSF and PsyMed Ventures, invites anyone at the forefront of the cutting-edge longevity and psychedelic fields to submit grant-funded proposals. The LSF and PsyMed are specifically encouraging applications from researchers working on projects related to using existing or novel psychedelics to manage, delay or reverse age-associated mental and brain diseases. They also are enthusiastic about proposals on mechanisms behind the complex effects elicited by psychedelic compounds, and any other breakthrough areas synergising the longevity and psychedelics fields.

Garri Zmudze

“Mental health is a vital yet often overlooked aspect of longevity – I believe a healthy mind is equally as important as a healthy body,” said Garri Zmudze, executive coordinator of the Longevity Science Foundation. “By funding research on psychedelics, the Longevity Science Foundation is contributing to a body of knowledge transforming brain health and longevity [2].”

“There is incredible innovation occurring in the development of psychedelic treatments for mental health,” said Lisa Ireland, president and CEO of the Longevity Science Foundation. “We are proud to announce this funding call to support visionaries and researchers dedicated to expanding our understanding of psychedelics. We encourage others to learn more about this growing field [2].”

“PsyMed has been active in the psychedelics space for several years, funding over 15 projects in the field,” said Matias Serebrinsky, co-founder and general partner at PsyMed Ventures. “We are thrilled to work with the LSF to explore new applications of these life-changing compounds and their benefits for human longevity [2].”

Applications for this funding call are accepted on a rolling basis until 30th June, 2023. To apply, visit https://longevity.foundation/apply.

[1] https://longevity.foundation/tpost/vf6xr08fn1-funding-call-announcement-aging-clocks
[2] https://longevity.foundation/tpost/gbgb5raxb1-funding-call-announcement-psychedelics-a